Literature DB >> 12030947

Peptic ulceration in general practice in England and Wales 1994-98: period prevalence and drug management.

J-Y Kang1, A Tinto, J Higham, A Majeed.   

Abstract

BACKGROUND: Little is known about the burden of peptic ulcer in the community. AIMS: To examine recent time trends in the period prevalence of peptic ulceration and its drug management, in England and Wales.
METHODS: For each year between 1994 and 1998, information on patients with a diagnosis of peptic ulceration was extracted from the General Practice Research Database.
RESULTS: The annual age-standardized period prevalence of peptic ulceration decreased from 3.3/1000 in 1994 to 1.5/1000 in 1998 for men, and from 1.8/1000 to 0.9/1000 for women. This decline was more evident among younger people, and among males registered with practices located in the most deprived electoral wards compared to those located in the least deprived. The proportion of patients receiving H2 receptor antagonists declined from 68% in 1994 to 41% in 1998. In contrast, the proportion prescribed proton pump inhibitors rose from 46% to 66%.
CONCLUSIONS: Over a 5-year period, the period prevalence of peptic ulceration has decreased markedly, especially among younger people and those from more deprived areas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12030947     DOI: 10.1046/j.1365-2036.2002.01261.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  8 in total

Review 1.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

2.  Clinical Efficiency and Safety of Magnetic-Controlled Capsule Endoscopy for Gastric Diseases in Aging Patients: Our Preliminary Experience.

Authors:  Shaoheng Zhang; Tao Sun; Yue Xie; Changhui Yu; Shaoqin Jin; Jianlin Yu; Hua Mao
Journal:  Dig Dis Sci       Date:  2019-04-29       Impact factor: 3.199

3.  Gastric Ulcer Complications after the Introduction of Proton Pump Inhibitors into Clinical Routine: 20-Year Experience.

Authors:  Friederike Eisner; Diana Hermann; Khaled Bajaeifer; Jörg Glatzle; Alfred Königsrainer; Markus A Küper
Journal:  Visc Med       Date:  2017-06-16

4.  Time trends in the incidence of peptic ulcers and oesophagitis between 1994 and 2003.

Authors:  Stefaan Bartholomeeusen; Jan Vandenbroucke; Carla Truyers; Carl Truyers; Frank Buntinx
Journal:  Br J Gen Pract       Date:  2007-06       Impact factor: 5.386

5.  When Should Antiplatelet Agents Be Resumed After Successful Endoscopic Hemostasis in Patients with Peptic Ulcer Bleeding?

Authors:  Jung-Wook Kim; Hyun Jin Park; Jae-Young Jang; Chi Hyuk Oh; Jae-Jun Shim; Chang Kyun Lee; Young Woon Chang
Journal:  Dig Dis Sci       Date:  2016-02-05       Impact factor: 3.199

6.  Has peptic ulcer disease changed during the past ten years in Korea? A prospective multi-center study.

Authors:  Hyun Joo Jang; Min Ho Choi; Woon Geon Shin; Kyung Ho Kim; Yong Woo Chung; Kyoung Oh Kim; Cheol Hee Park; Il Hyun Baek; Kwang Ho Baik; Sea Hyub Kae; Hak Yang Kim
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

7.  Trends in Peptic Ulcer Disease and the Identification of Helicobacter Pylori as a Causative Organism: Population-based Estimates from the US Nationwide Inpatient Sample.

Authors:  Bronislava Bashinskaya; Brian V Nahed; Navid Redjal; Kristopher T Kahle; Brian P Walcott
Journal:  J Glob Infect Dis       Date:  2011-10

8.  Analysis of gastroscopy results among healthy people undergoing a medical checkup: a retrospective study.

Authors:  Haosu Huang; Yanting Rong; Meng Wang; Zimeng Guo; Yanghua Yu; Zhenpu Long; Xiaoxiao Chen; Hanyue Wang; Junjie Ding; Lu Yan; Jie Peng
Journal:  BMC Gastroenterol       Date:  2020-12-09       Impact factor: 3.067

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.